![]() The proceeds of the issue will be utilised for capital expenditure, growth plans and debt repayment and will be finalised in consultation with the merchant bankers. The Board of Directors of Indian Hotels Co Ltd (IHCL) has approved the plan to raise up to Rs 3,000 crore through a rights issue. The subcommittee approved the issue price of Rs 149.35 per equity share, which is at a discount of Rs 6.23 per equity share or 4% per equity share to the floor price, for an aggregate value of Rs 2,500 crore to be allotted to the eligible qualified institutional buyers in the QIP. Last week, the bank had launched the qualified institutions' placement (QIP), setting the floor price at Rs 155.58 per equity share. State-owned Canara Bank closed its QIP, garnering a total of Rs 2,500 crore equity capital in the issue. The issue comprised a fresh issuance of shares, aggregating up to Rs 500 crore, and an offer for sale of up to Rs 2,280 crore by promoters and existing shareholders.Ĭanara Bank: Up 1.21%. The qualified institutional buyers' portion was booked 32.4 times, while the portions set aside for non-institutional investors and retail investors were subscribed 33.91 times and 1.35 times, respectively. The Rs 2,780 crore initial public offering of Aptus Value received strong demand and was subscribed 17.20 times between August 10-12, 2021. Oncology is one of the focus areas for Syngene and this global partnership will help us harness our individual expertise to develop a better product for the benefit of cancer patients worldwide.Aptus Value Housing Finance India: The stocks of housing finance company Aptus Value Housing Finance India debuted on bourses today at Rs 333 per share against an issue price of 353 per share. Manoj Nerurkar, chief operating officer, Syngene International added, "We are happy to partner with Artelo in developing ART27.13 for anti-cancer indications. "It is an honor to be a part of such an innovative delivery model that globally integrates the best in drug discovery and clinical development expertise to support Artelo in its efforts to develop future novel oncology drugs for the benefit of patients," stated Steve McConchie, chief executive officer of Aptus Clinical.ĭr. Aptus Clinical will develop and design an anti-cancer clinical study that is scientifically credible, ethically acceptable and operationally deliverable. It will also provide clinical development and regulatory expertise to the partnership. "This partnership is a premier example of how global partners with a common interest can be harnessed inside the exciting R&D environment in the United Kingdom."Īs part of the agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications. While a lot is already known about the drug's pre-clinical and clinical profile, we believe working alongside proven global talent will ensure that our new insights into ART27.13 are rapidly transitioned into the clinic," said Andrew Yates, PhD, ART27.13 Program Leader. ![]() "ART27.13 represents an important new therapeutic class of anti-cancer medicine.
0 Comments
Leave a Reply. |